BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,302.00
- Market cap
- ₹15,755 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.9×Sector 48.7×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.
AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
Other business update announcements
All →Alkem Laboratories Business Update
Alkem informed the exchange that US FDA completed inspection of its Mandva API facility with no Form 483 observations. The clean result confirms regulatory compliance.
Libas Consumer Products Business Update
Libas announced a 25% discount voucher for all registered shareholders, valid November 2026 to October 2027. Shareholders claim it via email with demat details.
GAIL (India) Business Update
GAIL revises Durgapur-Haldia and Dhamra-Haldia pipeline completion to March 2027 due to unavailability of hindrance-free fronts. No additional investment is required for either section.
Kirloskar Industries Business Update
Kirloskar Industries forwarded Q1 FY27 unaudited results of subsidiary KFIL to exchanges. The filing discloses revenue, profit, and key financial ratios for the September quarter.
OneSource Specialty Pharma Business Update
OneSource received a USFDA EIR with VAI classification for its Bengaluru SPD facility. This marks completion of the June 2026 inspection with no monetary penalty.
GP Eco Solutions India Business Update
GP Eco Solutions shared a factory showcase video of subsidiary Invergy India's first-phase manufacturing facility. The video highlights production capabilities, infrastructure, and product portfolio.